The Japanese government on March 7 announced new NHI prices for the FY2025 drug price revision, effective April 1. With…
BUSINESS
Sumitomo/Otsuka’s Blockbuster Hopeful Ulotaront Misses Primary Goals in PIII Schizophrenia Studies
Sumitomo Pharma and its global partner Otsuka Pharmaceutical said on July 31 that their hoped-to-be blockbuster ulotaront failed to hit the primary endpoints in two PIII studies conducted in the US for acutely psychotic adults with schizophrenia. The topline data…
To read the full story
Related Article
BUSINESS
- GE Healthcare Fully Acquires Nihon Medi-Physics
April 1, 2025
- Ono Pairs Up with Reborna to Discover CNS Disease Drugs
April 1, 2025
- Chugai CEO’s Pay Tops 400 Million Yen in 2024: Securities Report
April 1, 2025
- Sawai to Pick Up Sumitomo Pharma’s Digital Healthcare Unit
April 1, 2025
- Santen’s Myopia Drug Recommended for European Approval
April 1, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…